Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Navamedic Board/Management Information 2016

Aug 23, 2016

3668_iss_2016-08-23_38b8be3e-e4fe-44b0-8b02-98100d7c3c34.html

Board/Management Information

Open in viewer

Opens in your device viewer

Navamedic appoints new CFO

Navamedic appoints new CFO

Oslo, 23 August 2016 - Navamedic ASA (OSE: NAVA), today announces the

appointment of Toril Marie Ås as the new Chief Financial Officer of the company.

Ms. Ås has been Navamedic's interim CFO since 1 February 2016.

"We are pleased to announce the appointment of Toril Marie Ås as our new CFO.

With her extensive experience, Toril has been an invaluable addition to our

company and management team, and we are looking forward to working together with

Toril on a permanent basis," says Tom Rönnlund, Chief Executive Officer of

Navamedic.

Ms. Ås holds a M.Sc. in Business from Bodø Graduate School of Business, and a

M.Sc. in Management from London Business School. She has more than 20 years'

executive experience from service-, telecom- and media organisations. Prior to

joining Navamedic as interim CFO on 1 February 2016, ms. Ås held a position as

CFO for Telenor Media Invest. Ms. Ås is a Norwegian citizen, and will be based

at Navamedic's Oslo office.

For further information, please contact:

Tom Rönnlund, CEO, Navamedic. Telephone +46 727 320 321.

Navamedic ASA is a Norwegian medtech and pharmaceutical products company,

delivering products to patients, hospitals and pharmacies in the Nordic and

Benelux markets. The Group's Medtech business has developed and is currently

introducing the next generation of digital urine meter Sippi®. Navamedic's

Pharma and Healthcare business is a distributor of products supplied by a number

of pharmaceutical manufacturers. Navamedic is listed on the Oslo Stock Exchange

(ticker: NAVA).

This information is subject of the disclosure requirements pursuant to section

5-12 of the Norwegian Securities Trading Act.